These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 31480806)

  • 1. Severe Eosinophilic Asthma.
    Bakakos A; Loukides S; Bakakos P
    J Clin Med; 2019 Sep; 8(9):. PubMed ID: 31480806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologics in severe asthma: the overlap endotype - opportunities and challenges.
    Bakakos A; Loukides S; Usmani OS; Bakakos P
    Expert Opin Biol Ther; 2020 Dec; 20(12):1427-1434. PubMed ID: 32779950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary care of asthma: new options for severe eosinophilic asthma.
    Skolnik NS; Carnahan SP
    Curr Med Res Opin; 2019 Jul; 35(7):1309-1318. PubMed ID: 30880484
    [No Abstract]   [Full Text] [Related]  

  • 4. Biological treatments for severe asthma: A major advance in asthma care.
    Busse WW
    Allergol Int; 2019 Apr; 68(2):158-166. PubMed ID: 30792118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation.
    Nixon J; Newbold P; Mustelin T; Anderson GP; Kolbeck R
    Pharmacol Ther; 2017 Jan; 169():57-77. PubMed ID: 27773786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of airway inflammation in bronchial asthma.
    Nakagome K; Nagata M
    Auris Nasus Larynx; 2011 Oct; 38(5):555-63. PubMed ID: 21334836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mepolizumab for the reduction of exacerbations in severe eosinophilic asthma.
    Russell R; Brightling C
    Expert Rev Respir Med; 2016 Jun; 10(6):607-17. PubMed ID: 27058452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologics or immunotherapeutics for asthma?
    Tay HL; Foster PS
    Pharmacol Res; 2020 Aug; 158():104782. PubMed ID: 32275962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Airway autoimmunity, asthma exacerbations, and response to biologics.
    Venegas Garrido C; Mukherjee M; Bhalla A; Nair P
    Clin Exp Allergy; 2022 Dec; 52(12):1365-1378. PubMed ID: 35993511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eosinophils Target Therapy for Severe Asthma: Critical Points.
    Brussino L; Heffler E; Bucca C; Nicola S; Rolla G
    Biomed Res Int; 2018; 2018():7582057. PubMed ID: 30498762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.
    Emma R; Morjaria JB; Fuochi V; Polosa R; Caruso M
    Ther Adv Respir Dis; 2018; 12():1753466618808490. PubMed ID: 30354852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody therapy for the management of severe asthma with eosinophilic inflammation.
    Ohta K; Nagase H; Suzukawa M; Ohta S
    Int Immunol; 2017 Jul; 29(7):337-343. PubMed ID: 28910970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologics in Asthma: A Molecular Perspective to Precision Medicine.
    Salter B; Lacy P; Mukherjee M
    Front Pharmacol; 2021; 12():793409. PubMed ID: 35126131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.
    Al Efraij K; FitzGerald JM
    Expert Rev Clin Pharmacol; 2018 Jul; 11(7):669-676. PubMed ID: 29972739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B; Xue L; Pavord ID
    Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma.
    Bagnasco D; Ferrando M; Varricchi G; Puggioni F; Passalacqua G; Canonica GW
    Front Med (Lausanne); 2017; 4():135. PubMed ID: 28913336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging interleukin receptor antagonists for the treatment of asthma.
    Al Efraij K; FitzGerald JM
    Expert Opin Emerg Drugs; 2017 Sep; 22(3):275-283. PubMed ID: 28832218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mepolizumab versus placebo for asthma.
    Powell C; Milan SJ; Dwan K; Bax L; Walters N
    Cochrane Database Syst Rev; 2015 Jul; (7):CD010834. PubMed ID: 26214266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eosinophil apoptosis as a therapeutic target in allergic asthma.
    Ilmarinen P; Kankaanranta H
    Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):109-17. PubMed ID: 24148899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eosinophils, the IL-5/IL-5Rα axis, and the biologic effects of benralizumab in severe asthma.
    Matucci A; Maggi E; Vultaggio A
    Respir Med; 2019; 160():105819. PubMed ID: 31734469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.